Exploring new ways to improve brain function in Alzheimer's and related conditions
Chemical and Molecular Tools for Modulating GPCR Function
This study is exploring how certain safe, non-hallucinogenic compounds can help improve brain function and emotional health, with the goal of creating better treatments for conditions like Alzheimer's that can boost memory and reduce anxiety.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-11082218 on NIH RePORTER |
What this research studies
This research focuses on understanding how certain small molecules, known as psychoplastogens, can enhance the structure and function of neurons in the prefrontal cortex, which is crucial for cognitive abilities and emotional regulation. By investigating non-hallucinogenic versions of these compounds, the research aims to develop safer and more effective treatments for neurodegenerative diseases like Alzheimer's. Patients may benefit from therapies that restore cognitive function and reduce symptoms such as anxiety and lack of motivation. The approach includes both laboratory studies and potential clinical applications to optimize these compounds for patient use.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Alzheimer's disease or related neurodegenerative conditions who experience cognitive decline and emotional disturbances.
Not a fit: Patients with non-neurodegenerative cognitive impairments or those not diagnosed with Alzheimer's or related conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments that improve cognitive function and emotional well-being for patients with Alzheimer's disease and related disorders.
How similar studies have performed: Previous research has shown promise with psychoplastogens in enhancing neuroplasticity, but the focus on non-hallucinogenic variants is a novel approach.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Olson, David E — University of California at Davis
- Study coordinator: Olson, David E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.